Indian pharma industry may achieve double-digit growth by 2030 via regulatory support from Government, says pharma industry body
"Ayushman Bharat Scheme that brings 40 per cent of the poor population under state-funded insurance cover also broadens possibilities to all healthcare ecosystem players including pharmaceutical companies," Secretary-General of Indian Pharmaceutical Alliance, Sudarshan Jain said.
Ahmedabad: Indian pharmaceutical industry can achieve a target of double-digit growth by 2030 through a host of measures including regulatory support from the government like an increase in budgetary allocations for healthcare and promotion of innovation, a pharmaceutical industry body said.
Setting a coherent pricing policy framework, simplifying regulatory approval processes, creating a separate Ministry of Pharmaceuticals and dedicated zones for the creation of medicines, are some of the ways that the government could help the industry achieve the ambitious target of becoming a USD 120-130 billion industry by 2030, it said.
"We are seeking from government stable pricing policy. Whatever government decides in terms of drug pricing should be kept stable for at least five years, Secretary-General of Indian Pharmaceutical Alliance, Sudarshan Jain said here.
The government should also aim to increase expenditure on healthcare from about 1.2 per cent to 2.5 per cent of GDP in the next five years, and to 5 per cent by 2030, for the industry to grow, Jain said.
"Ayushman Bharat Scheme that brings 40 per cent of the poor population under state-funded insurance cover also broadens possibilities to all healthcare ecosystem players including pharmaceutical companies," he said.
As per a report prepared by the IPA, at its current rate of 7-8 per cent CAGR, the Indian pharmaceutical industry is expected to grow about USD 80 to 90 billion by 2030.
With a double-digit growth of 11-12 per cent, the industry can grow about USD 65 billion by 2024 and about USD 120 to 130 billion by 2030.
Increased accessibility and affordability of healthcare, potential breakthroughs in next-generation innovative products, strong growth in the US market, and increased growth in large underpenetrated markets such as Japan and China are some of the ways for the industry to grow, Jain added.
The industry body has also raised the demand for reducing GST on all drugs to a uniform 5 per cent, he said.
Zydus Cadila CMD Pankaj Patel, a member company of the Alliance, said that innovation remains the focus for the future, and IPA is working in the direction of strengthening the innovation ecosystem in the Indian pharma industry.
"The future is innovation, and IPA has taken innovation as a theme. It is working on innovation, in terms of collaboration between government institutions, industry, and making innovation go to the next level for the Indian pharma industry to grow. India has the capacity to develop drugs and sell it to the world," he said.